| International Session（Panel Discussion）1(JSGE・JGES・JSGS) |
| Fri. November 1st 10:00 - 12:00 Room 7: Portopia Hotel South Wing Ohwada C |
Prognostic efficacy using LRG assessment differs between Crohn's disease and ulcerative colitis
|
|||
| Yusuke Honzawa1, Naohiro Nakamura1, Makoto Naganuma1 | |||
| 1Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University | |||
|
|||
|
|||
| Background: Although leucine-rich a2-glycoprotein (LRG) is closely associated with endoscopic severity, the relationship of LRG with long-term prognosis in patients with IBD is still unclear. The aim of study is to investigated the usefulness of LRG for predicting clinical remission (CR) in patients with IBD. Methods: Clinical information including LRG was retrospectively collected from 295 patients with IBD (CD;101, UC;194) between 2020 and 2023. Result: LRG level did not correlate with clinical activity. In patients with both CD and UC, LRG level strongly correlated with CRP level (CD; r=0.78, UC; 0.74) and serum albumin level (r =-0.69, -0.53). While multivariate analysis revealed that only LRG (p=0.02) was an independent factor for predicting CR in patients with CD, serum albumin (p=0.02) and quantitative fecal immunochemical test (p<0.01), not LRG was a predictive factor for CR in patients with UC. Cumulative remission rate was also higher in CD patients with LRG less than 13.8 compared to those with LRG greater than 13.8 in patients with L1, L3 or B2+B3 of Montreal calcification. Conclusion: LRG was closely associated with blood biomarkers in both CD and UC. However, factors for predicting CR were different between patients with CD and UC. LRG evaluation was useful in predicting the prognosis of CD, even in patients with small intestinal lesions, intestinal stenosis, or previous/present fistulas. |
|||
|
Index Term 1: IBD Index Term 2: LRG |
|||
| Page Top | |||